<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003022</url>
  </required_header>
  <id_info>
    <org_study_id>97-021</org_study_id>
    <secondary_id>CDR0000065607</secondary_id>
    <secondary_id>NCI-G97-1267</secondary_id>
    <nct_id>NCT00003022</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer</brief_title>
  <official_title>Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
      tumor-killing substances to them without harming normal cells.

      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating
      patients who have leptomeningeal metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Define the clinical toxicities of intrathecal iodine I 131 monoclonal antibody 3F8
           (I-3F8) in patients with GD2 positive leptomeningeal neoplasms.

        -  Determine whether I-3F8 can detect GD2 positive leptomeningeal tumors.

        -  Measure the cerebrospinal fluid (CSF) levels and serum pharmacokinetics of I-3F8 in
           these patients.

      OUTLINE: This is a dose escalation study.

      Patients receive a single injection of intraventricular or intrathecal iodine I 131
      monoclonal antibody 3F8. Patients without objective disease progression and no grade 3 or 4
      toxicity 6 weeks after the first dose may receive a second injection.

      Cohorts of at least 3 patients are entered at escalating doses of I-3F8. If grade 3 or worse
      toxicity occurs in 1 or more of 3 patients at a given dose level, then 3 additional patients
      are accrued at that level. If 2 or more of 6 patients at a given dose level experience grade
      3 or worse toxicity, then that dose is declared the maximum tolerated dose (MTD).

      Patients are followed weekly for 4 weeks.

      PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study over 2-3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Intraocular Melanoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Neuroblastoma</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody 3F8</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignancy expressing GD2, including, but not limited to:

               -  Medulloblastoma/primitive neuroectodermal tumor of the CNS

               -  Malignant glioma

               -  Neuroblastoma

               -  Retinoblastoma

               -  Ependymoma

               -  Sarcoma

               -  Melanoma

               -  Small cell lung carcinoma

               -  Other tumor types must have GD2 expression confirmed by immunohistochemical
                  staining

          -  Cerebrospinal fluid or leptomeningeal disease that is refractory to conventional
             therapy or for which no conventional therapy exists

          -  Prior measurable human anti-mouse monoclonal antibody titer allowed

        PATIENT CHARACTERISTICS:

        Age:

          -  3 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 50,000/mm^3

        Hepatic:

          -  Bilirubin less than 3 mg/dL

        Renal:

          -  Creatinine less than 2 mg/dL

          -  Blood urea nitrogen less than 30 mg/dL

        Other:

          -  May have active malignancy outside the central nervous system

          -  No obstructive hydrocephalus

          -  No CNS grade 3 or 4 toxicity as a consequence of prior treatments

          -  No life threatening infection

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior monoclonal antibody treatment allowed

        Chemotherapy:

          -  Prior chemotherapy allowed

          -  Must have recovered from all hematopoietic and neurologic side effects of prior
             chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior radiotherapy allowed

          -  At least 6 weeks since prior cranial or spinal irradiation

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Kramer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007 Dec 1;25(34):5465-70.</citation>
    <PMID>18048828</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>retinoblastoma</keyword>
  <keyword>intraocular retinoblastoma</keyword>
  <keyword>extraocular retinoblastoma</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>localized Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

